Of the 51 evaluable patients, two achieved a partial response – an estrogen receptor (ER) positive, HER2 negative breast cancer patient with unknown PI3K pathway status; and a patient with Cowden's syndrome (germline PTEN mutation) who had developed lung cancer. The gene discussed is ERBB2; the disease is breast cancer.